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Abstract Objectives: The aim of this study was to assess
the concurrent validity between the identiﬁcation of sub-
optimal treatment based on clinical information and
computer generated indicators. Indicators that are
associated with sub-optimal treatment in one of the four
steps of asthma management were assessed.
Design: The ability of each indicator to identify patients
with sub-optimal asthma treatment from computerised
general practitioner (GP) prescription records was
assessed by comparing them with the results of an
individual patient assessment using clinical data.
Setting: Chronic asthma patients (n=146) registered
with 16 Dutch GPs.
Main measures: The sensitivity and positive predictive
value (PPV) of each performance indicator was deter-
mined.
Results: The step-1 indicator, focusing on patients not
prescribed a short-acting b-agonist, had an acceptable
sensitivity (0.86), but a low PPV (0.52). The two step-2
indicators, targeting under-prescription of inhaled cor-
ticosteroids, had sensitivities of 0.74 and 0.37 and PPVs
of 0.46 and 0.71, respectively. The step-3 indicator,
which targeted under-dosing of inhaled corticosteroids,
had a sensitivity of 0.07 and a PPV of 0.2. The fourth
indicator, focusing on under-prescription of long-acting
b-agonists, could not be validated due to inadequate
numbers of patients with severe asthma in our study
sample.
Discussion: None of the indicators investigated was
considered valid for assessing prescriber performance,
despite having good face and content validity. Perfor-
mance indicators that have not been validated can only
provide a broad-brush approach for assessing prescrib-
ing quality and should be used with extreme caution.
Keywords Quality indicators Æ Drug therapy Æ Asthma
Introduction
Quality assessment and improvement is receiving atten-
tion world wide. Information on health-care quality is
being demanded by policy makers, health-care profes-
sionals and the general public alike [1, 2, 3, 4, 5, 6, 7].With
the majority of doctor–patient encounters in general
practice resulting in a prescription for drug treatment, the
quality of prescribing in general practice is an important
issue [8]. Prescribing indicators for general practice have
been used in several countries, for example, in the US,
UK,Australia andNetherlands [7]. They are likely tokeep
a central role in programs to optimise care andare used for
a range of purposes. The most important are (1) identiﬁ-
cation of patients receiving sub-optimal care, (2) moni-
toring of change or assessing the outcome of interventions
and (3) identiﬁcation of poor performers for purposes of
postgraduate education or accountability and regulation
[7, 9]. However, as illustrated by Pringle et al., creating
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meaningful indicators from accurate data is a challenge
[7]. This is especially the case for conditions that require a
complex treatment regime according to severity, such as
asthma.
Asthma is a chronic condition aﬀecting more than
8% of adults in Western Europe. It is commonly treated
in general practice [10]. Since the early 1990s, interna-
tional asthma treatment guidelines have been available,
which provide clear, well-accepted recommendations
regarding optimal asthma management. Asthma is a
variable disease, where the severity is determined by
symptoms and lung function. The international con-
sensus distinguishes four diﬀerent levels of severity, each
demanding a diﬀerent treatment with medicines, i.e.
optimal asthma pharmacotherapy is a step-wise process
with treatment diﬀering for each of the four asthma
severity classes [11, 12, 13].
Various indicators have been developed for assessing
the quality of asthma treatment in general practice,
based on the recommendations in the international
guidelines [14, 15, 16, 17, 18, 19, 20, 21]. Most indicators
are derived from easily accessible prescription data.
Commonly used asthma indicators focus on the pro-
portion of patients prescribed a particular medication,
such as inhaled corticosteroids or short-acting b-agon-
ists, without taking into account diﬀerences in asthma
severity [16, 17, 22]. An international collaboration
developed a set of ﬁve asthma-prescribing indicators,
attempting to diﬀerentiate among asthma severity clas-
ses using drug-based proxies. These indicators were used
to evaluate an international intervention for improving
asthma care in general practice [18, 23, 24]. The face and
content validity of these indicators was considered good
[23, 24]. Face validity indicates that the indicator ap-
pears to measure what it purports to and content
validity means that the indicator is considered to be
relevant. However, later work showed little correlation
between indicators designed to target the same sub-
optimal treatment pattern [19], suggesting that face and
content validity alone may not be adequate for deter-
mining indicator validity. Concurrent validity, that is,
comparison with a reference measure, is needed to fully
determine the validity of performance indicators. The
aim of this study was to assess the concurrent validity
between the identiﬁcation of sub-optimal treatment
based on clinical information and computer generated
indicators.
Materials and methods
Study population and recruitment procedure
The Registration Network Groningen (RNG) is a general prac-
tice database in the northern Netherlands. At the time of the
study, the RNG included 30,486 patients registered with 16
general practitioners (GPs). Participating GPs use the database in
clinical practice in place of paper medical records. Due to this, all
prescriptions can be linked to the indication asthma, as diagnosed
by the GP.
All patients aged 18–49 years with an asthma medication
(Anatomical Therapeutic Chemical classiﬁcation–ATC [25] group
R03) or an asthma contact (International Classiﬁcation of Primary
Care-ICPC [26] code R96) during 1997 were selected from this
database. Patients who received asthma medications for non-
asthma indications were excluded, as well as patients who were no
longer registered with an RNG doctor. Data from 1997 were used
for recruitment to ensure that patients had chronic asthma in the
study period. Eligible patients were invited to an individual study
appointment by their GP, who unlocked the ‘‘key’’ that is used in
the database to safeguard anonymity. A reminder letter was sent to
non-respondents within 3 months of the initial invitation. Anony-
mous data for eligible non-responders were used for comparison
regarding age, sex and asthma medication use. The local medical
ethics committee approved the study, and informed consent was
obtained from each participant.
Validation process
We validated indicators that targeted sub-optimal treatment pat-
terns related to four steps included in the 1997 National Institutes
of Health (NIH guidelines) [12].
Step 1. Under-treatment of short-acting inhaled b-agonists for
all asthma patients
Step 2. Under-treatment of inhaled corticosteroids for mild,
moderate or severe persistent asthma
Step 3. Inadequate dose of inhaled corticosteroids for moderate
or severe persistent asthma
Step 4. Under-treatment of inhaled long-acting b-agonists for
severe persistent asthma
Every patient was classiﬁed as being sub-optimally treated
within every severity level of asthma in two ways: (1) using the
computer-based prescribing indicators (the ‘‘indicators’’) and (2)
using information on currently used medication in relation to
symptoms and lung function assessed in a study appointment (the
‘‘individual patient assessment’’). The latter classiﬁcation was used
as the reference value for the validation, i.e. the validation process
checked to what extent the identiﬁcation of sub-optimal treatment
based on clinical information can be reproduced by computer
generated indicators.
Indicators
The indicators validated in this study have been previously devel-
oped and used internationally for assessing the quality of pre-
scribing for chronic adult asthma [18, 20, 24]. Detailed information
on the development and use of the indicators has been published
elsewhere [19]. In this study, indicators were calculated using data
from the RNG database from 1999–2000. For each participating
asthma patient, prescription data for the 12-month period prior to
the study appointment were obtained retrospectively from the GP
database. The indicators, based on the sub-optimal treatment
patterns related to four steps included in the 1997 National Insti-
tutes of Health (NIH guidelines) [12] were calculated as follows.
Step 1 indicator. The patient is not prescribed an inhaled
short-acting b-agonist during the 1-year
period prior to the study appointment
Step 2A indicator. The patient is not prescribed an inhaled
corticosteroid during a 1-year period prior to
the study appointment
Step 2B indicator. The patient is not prescribed an anti-
inﬂammatory agent (either corticosteroid or
cromoglycate), but is prescribed an amount
of inhaled short-acting b-agonist for daily
use over a 1-year period prior to the study
appointment
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Step 3 indicator. The patient is prescribed a low-dose inhaled
corticosteroid ( £ 400 lg budesonide or
equivalent daily, Table 1) in combination
with an inhaled short-acting b-agonist more
than once daily over a 1-year period prior to
the study appointment
Step 4 indicator. The patient is prescribed a high-dose inhaled
corticosteroid (>600 lg budesonide or
equivalent, Table 1), and an inhaled short-
acting b-agonist at least twice daily over a
1-year period prior to the study appoint-
ment, but no long-acting b-agonist
The step-2B, step-3 and step-4 indicators incorporate the
average daily amount of short-acting b-agonist over a 1-year period
per patient. This is used in these types of indicators as a proxy for
asthma severity, assuming that higher b-agonist use is associated
with more severe asthma.
Individual patient assessment
The information needed for the reference measure on sub-optimal
treatment patterns was collected in an individual study appoint-
ment. Each participating patient attended a single study appoint-
ment (May 2000–December 2000) with a trained research assistant.
During this appointment, a questionnaire on symptoms and med-
ication was completed. The questions referred to symptoms of
asthma, such as dyspnoea and night symptoms, during the previous
week and to drug use in the previous week, asking for the name of
the drug and the number of doses used per day for every drug.
Patients were asked to bring all current asthma medications to the
study appointment and were asked about having spare bronchod-
ilator inhalers, which may distort prescription patterns, as seen in
computerised databases. Each patients forced expiratory volume at
1 s (FEV1) was determined according to the standards of the
American Thoracic Society, using a Microlab 3300 spirometer
(Micro Medical Ltd., Rochester, Kent UK). For each participant,
the best of three readings was used. Each patients treatment regime
was then classiﬁed as being either optimal or sub-optimal, taking
into account severity and current medication, according to the
explicit criteria speciﬁed in the NIH guideline (Table 1). For
example, a patient with symptoms more than twice a week, but not
daily, or exacerbations that may aﬀect activity or night time
symptoms more than twice a month, but not weekly, or a sub-
optimal, but ‡80% predicted FEV1, was classiﬁed as a class-2 pa-
tient. According to the NIH instructions, the presence of at least
one of the features of severity is suﬃcient to place a patient in that
severity class. An individual was assigned the most severe class in
which a feature occurred.
Sample size
We deﬁned that a valid indicator would require both a sensitivity
and positive predictive value (PPV) of at least 0.7 for use in quality
assessment. With a 95% conﬁdence interval of 0.1, we calculated
that at least 84 asthma patients would be needed to validate each
indicator [27]. The RNG database included 369 patients meeting
our inclusion criteria, and we decided to invite all eligible patients
to participate in the study to ensure that our sample size require-
ments were met.
Analysis
Since each indicator can be viewed as a type of diagnostic test that
identiﬁes sub-optimal treatment, we assessed indicator validity in
terms of sensitivity and PPV. These were calculated according to
Altman [28]. The sensitivity of an indicator denotes the proportion
of cases of sub-optimal treatment found in the individual assess-
ment method, which is also identiﬁed by the indicator. The PPV is
the proportion of cases identiﬁed by the indicator that is conﬁrmed
in the individual assessment.
Three of the indicators (step 2B, step 3 and step 4) incorporated
levels of daily short-acting b-agonist use as a proxy for asthma
severity. The association between short-acting b-agonist use and
asthma severity was explored using rank correlation (Kendalls
tau). A perfect correlation yields a Kendalls tau of 1, while a
Kendalls tau of 0 indicates no relationship. In order to assess if the
cut-oﬀ levels used in each indicator could distinguish among the
Table 1 Severity classiﬁcation criteria and pharmacotherapy recommendations from the 1997 National Institutes of Health asthma
guideline. FEV1 forced expiratory volume at one second, PEV peak expiratory ﬂow
Asthma severity
class




Symptoms: two times a week or less. Asymptomatic and normal
PEF between exacerbations. Exacerbations brief. Nighttime
symptoms: two times a month or less. Lung function: FEV1





Symptoms: > two times a week but < once a day. Exacerbations
may aﬀect activity. Nighttime symptoms: > two times a month.
Lung function: FEV1 or PEF ‡ 80% predicted
Short-acting inhaled b-agonist




Symptoms: daily. Daily inhaled short-acting b-agonist use.
Exacerbations aﬀect activity. Exacerbations two times a week
or more. Nighttime symptoms: > once a week. Lung function:
FEV1 or PEF > 60% and < 80% predicted
Short-acting inhaled b-agonist
as needed and medium
dose inhaled corticosteroid





Symptoms: continual. Limited physical activity. Frequent exacerbations.
Nighttime symptoms: frequent. Lung function: FEV1 or PEF 60%
predicted or less
Short-acting inhaled b-agonist
as needed and high dose
nhaled corticosteroid and inhaled
long-acting b-agonist and/or
ipratropium bromide
*The presence of one of the features of severity is suﬃcient to place
a patient in that category. An individual should be assigned to the
most severe grade in which any feature occurs
Low-dose inhaled corticosteroid is 200–400 lg budesonide (or
equivalent) daily
Medium-dose inhaled corticosteroid is 400–600 lg budesonide
(or equivalent) daily
High-dose inhaled corticosteroid is >600 lg budesonide (or
equivalent) daily
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relevant asthma severity classes, we performed a receiver operating
curve (ROC) analysis. On ROC curves, the optimal cut-oﬀ points
can be found at the point where the curve begins to ﬂatten.
Results
Of the 369 eligible patients identiﬁed from the database,
146 were willing to participate in the study. Patient
characteristics and medication use are shown in Table 2.
Current medication determined at the study appoint-
ment was higher than that obtained from the prescrip-
tion database. Current short-acting b-agonist use was
reported by 101 (69.2%), inhaled corticosteroids by 96
(65.8%), cromoglycates 8 (5.4%), long-acting b-agonists
by 23 (15.8%) and ipratropium bromide by 19 (13.0%)
participants. Of the patients not using a short-acting
b-agonist, nine reported use of ipratropium bromide,
and another ﬁve reported use of formoterol.
Non-respondent characteristics
Data from the GP database showed no diﬀerence with
respect to gender between non-respondents and partici-
pating patients (58.2% and 57.8% female, respectively).
Participating patients were slightly older (39.8 years
versus 35.8 years, P<0.05). There were no signiﬁcant
diﬀerences between participating and non-responding
patients in the mean volume prescribed per patient for
inhaled short-acting b-agonists, inhaled corticosteroids,
inhaled anticholinergics and oral salbutamol.
Validation of the indicators
Table 3 shows the sensitivity and PPVs for each indi-
cator. The validity of the step-4 indicator could not be
determined due to an insuﬃcient number of patients
with persistent severe asthma (severity class 4).
The step-1 indicator had a sensitivity of 0.86, showing
that prescription data correctly identiﬁed 86% of all
patients without a short-acting b-agonist, as identiﬁed in
the individual assessment. The PPV of 0.52 indicates
that just over half of the patients identiﬁed by the indi-
cator as not having a short-acting b-agonist prescribed
during the study period actually did not have medication
at the study appointment. The others did have this
medication with them at the study appointment, either
from earlier prescriptions or from prescriptions by other
prescribers.
The step-2A indicator identiﬁed 74% of patients who
were not prescribed an inhaled corticosteroid and who,
according to their severity, should be prescribed this
drug group. However, of all patients found by the
indicator without an inhaled corticosteroid, less than
half (PPV=0.46) were conﬁrmed by individual assess-
ment. The step-2B indicator had a slightly lower sensi-
tivity than the step-2A indicator, despite targeting the
same sub-optimal treatment pattern. The majority
(71%) of patients identiﬁed by this indicator as in need
of an inhaled corticosteroid were conﬁrmed upon
the individual assessment. The remaining 29%, upon
individual assessment, were either currently using an
anti-inﬂammatory agent or were not high users of their
short-acting b-agonist or, according to their severity
classiﬁcation, did not need an anti-inﬂammatory agent.
The step-3 indicator was the poorest performing
indicator. This indicator was designed to detect patients
with severity class 3 or higher who were prescribed a
sub-optimal inhaled corticosteroid dose. However, it
detected only 7% of the patients found upon individual
assessment to have an inadequate corticosteroid dose.
Furthermore, just 20% of the patients identiﬁed by the
indicator with a sub-optimal dose were conﬁrmed as
having a sub-optimal corticosteroid dose upon individ-
ual assessment.
Short-acting b-agonist use as a proxy for asthma severity
While higher short-acting b-agonist use was signiﬁcantly
associated with increasing asthma severity (Kendalls
tau=0.307, P<0.001), the wide standard deviations
show considerable overlap in short-acting b-agonist use
among the diﬀerent asthma severity levels (Table 4).
Table 2 Characteristics of




Mean age (years) ±SD 39.8±8.3 39.8±8.3
Number of females (%) 85 (58.2%) 85 (58.2%)
Mean lung function (% predicted ±SD) 83.5±17.9
Medications Number of patients (%)
Inhaled short-acting b-agonists 86 (58.9%) 101 (69.2%)
Inhaled corticosteroids 90 (61.6%) 96 (65.8%)
Inhaled cromoglycates 6 (4.1%) 8 (5.4%)
Inhaled long-acting b-agonists 27 (18.5%) 23 (15.8%)
Inhaled ipratropium bromide 18 (12.3%) 19 (13.0%)
Asthma severity Number of patients (%)
Class 1 51 (34.9%)
Class 2 9 (6.2%)
Class 3 70 (47.9%)
Class 4 16 (11.0%)
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The step-2B indicator used a cut-oﬀ point for daily
short-acting b-agonist use (200 lg of salbutamol daily or
equivalent) to identify patients with a severity class of
more than one from prescription data. As seen in
Fig. 1a, this cut-oﬀ point correctly classiﬁed only 58.7%
of all patients. The step-3 indicator used a cut-oﬀ point
of high daily short-acting b-agonist use (400 lg salbu-
tamol daily or equivalent) to identify patients of a
severity class of more than two; however, this cut-oﬀ
point correctly classiﬁed only 43.9% of patients
(Fig. 1b). Neither curve ﬂattens considerably at any
point, indicating that no optimal short-acting b-agonist
levels could be identiﬁed.
Patients were asked during the study appointment
about having spare bronchodilator inhalers. More than
half of the patients being prescribed a short-acting
b-agonist reported using multiple inhalers simulta-
neously (55.7%). Of these, 50.7% reported having one
spare inhaler, 34.3% kept two spares and the remaining
14.9% kept between three and ﬁve extra short-acting
b-agonist inhalers.
Discussion
In this study, we evaluated the concurrent validity of ﬁve
performance indicators derived from computerised pre-
scription data for assessing the treatment of asthma.
Two general indicators, which looked at the total
number of patients prescribed short-acting b-agonist or
inhaled corticosteroids, had reasonable sensitivities, but
low PPVs. The two indicators that incorporated proxies
for asthma severity had much lower sensitivities and
varied PPVs.
While the response rate in this study was rather low,
there is no reason to believe that this would aﬀect the
outcomes of our validation study. An adequate number
of patients was recruited to validate four of the ﬁve
indicators. No diﬀerence was seen between participants
Table 3 Sensitivity and positive
predictive values for each
indicator (95% conﬁdence
intervals)
Indicator Relevant asthma severity




Step-1 indicator All severity classes (n=146) 0.86 (0.71–0.95) 0.52 (0.38–0.65)
Step-2A indicator Severity classes 2, 3 & 4 (n=95) 0.74 (0.57–0.88) 0.46 (0.33–0.60)
Step-2B indicator Severity classes 2, 3 & 4 (n=95) 0.37 (0.19–0.58) 0.71 (0.42–0.92)
Step-3 indicator Severity classes 3 & 4 (n=86) 0.07 (0.00–0.32) 0.20 (0.00–0.72)
Step-4 indicator Severity class 4 (n=16) Not validated due to
inadequate sample size
Table 4 Mean volume short-acting b-agonist amount prescribed
per patient per day. Mean volume is presented in deﬁned daily
doses (DDDs) [27]. 1 DDD is 800 lg salbutamol (or equivalent);














Class 1 23 0.24±0.31
Class 2 9 0.46±0.60
Class 3 51 0.60±0.60
Class 4 16 1.14±0.98
Fig. 1 Receiver operator curves
(ROC) of mean deﬁned daily
doses of short-acting b-agonist




classes. a Identiﬁcation of
patients in severity classes
greater than one. b
Identiﬁcation of patients in
severity classes greater than two
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and non-respondents with respect to gender and the use
of the diﬀerent asthma medications, although partici-
pating patients were slightly older.
We used a general practice database for calculating
the prescribing indicators. This database gives an accu-
rate account of all treatments prescribed by a GP to
patients diagnosed with asthma. In the Netherlands,
asthma medications are available only on prescription,
and, in general practice, patients register with a single
GP. Thus, the database contains complete records
regarding the asthma management of GPs. Pharmacy
records or claims data without information on disease
are considered less reliable in identifying patients with
asthma [29]. A limitation of using a GP database is that
it does not register prescriptions from specialists. In the
Netherlands, patients referred to a specialist may ini-
tially receive a prescription from the specialist, but
generally return to their GP for further medication
supply. For chronic medication, this is expected to result
in a slight underestimation of medication when looking
at a GP database during a 1-year period.
A GP prescription database can never fully reﬂect
actual use of medications. It overestimates actual use
when patients do get prescriptions, but are not collecting
or using the medication. However, it may underestimate
actual use when patients use their medication intermit-
tently, and, therefore, do not need a new prescription
during a 1-year period. In the Netherlands, one pre-
scription may be valid for a maximum of a 3-month
supply, but for medication that is used intermittently (‘‘as
needed’’), a prescription may cover a longer period. This
is expected to be the case for some relief medication, such
as inhaled short-acting b-agonists, but it is also known
that asthma patients sometimes use their inhaled corti-
costeroids intermittently. This could explain the ﬁnding
that the number of patients identiﬁed from the GP
database on certain medications during the study period
was somewhat lower than as determined during the study
appointment with the patients themselves. Self-reported
medication use, by patient interview, has been shown to
be a reliable method of obtaining current medications
[30, 31, 32]. In this study, the accuracy of self-reported
medication use was further improved by having patients
bring their asthma medications to the study appoint-
ment. This would include specialist-prescribed medica-
tion as well as medication prescribed prior to the study
period, but still used.
A limitation of this study is that the clinical assess-
ment of treatment quality referred to the previous week,
while prescribing indicators were based on prescribing in
the previous year. This may have led to an underesti-
mation of the validity of the prescribing indicators, since
asthma severity might have changed during the preced-
ing year. However, four of the indicators (step1, step 2A,
step 2B and step 3) identify sub-optimal prescribing, in
particular under-treatment, for several severity steps.
Sub-optimal prescribing for step 1 includes, by deﬁni-
tion, sub-optimal prescribing for steps 2, 3 and 4. This
implies that changes in severity are covered by these
indicators, with the exception of the step-4 indicator,
which could not be validated due to lack of data.
The sensitivity and PPVs required for validity vary
depending on the purpose for which the indicator is to be
used. If an indicator is being used to identify patients with
potential treatment problems, then it is important that the
initial screening process identiﬁes as many patients as
possible who then undergo further, more accurate testing.
Thus, for this purpose, indicators should have a high
sensitivity. Of the ﬁve indicators validated in this study,
both step 1 and step 2A indicators could be considered
valid screening indicators; though still far from ideal, no
better alternatives exist. The step-1 indicator identiﬁed
86% of all patients without an inhaled short-acting
b-agonist, while the step 2A indicator detected 74% of
patients not prescribed an inhaled corticosteroid who
should have one according to their severity classiﬁcation.
If an indicator is being used to monitor changes in
drug utilisation or to assess the outcome of an inter-
vention, then one may be satisﬁed with identifying only
a selection of the patients of interest. In this case, the
PPV becomes relatively more important than the sensi-
tivity. Thus, if one is satisﬁed with monitoring changes
or intervention outcomes in a sub-sample of patients, the
step-2B indicator could be considered valid. Although
this indicator identiﬁed less than half of all patients
needing an inhaled corticosteroid, more than 70% of the
patients identiﬁed were conﬁrmed as needing an inhaled
corticosteroid upon the individual assessment.
One of the common uses of prescribing indicators is to
assess the performance of doctors. To be considered valid
for assessing performance, an indicator needs to identify
as many sub-optimally treated patients as possible while
being certain that the all the patients identiﬁed are actually
being treated sub-optimally. That is, both the sensitivity
and PPVs should be suﬃciently high. Clearly, none of the
indicators based on prescription data validated in this
study can be considered valid for this purpose.
A major problem aﬀecting the validity of three of the
indicators studied (step 2B, step 3 and step 4) was the
inadequacy of using the prescription volume of short-
acting b-agonist as proxy of asthma severity. While we
observed a signiﬁcant relationship between short-acting
b-agonist use and asthma severity class, the range of use
was extremely wide, and no clear cut-oﬀ points could be
found that distinguished clearly among the diﬀerent
severity classes. More than half of the patients reported
using multiple short-acting b-agonist inhalers simulta-
neously. Given the role of these medications as symptom
relievers, it is understandable that patientsmay keep spare
inhalers to ensure that one is always readily available.
When calculating the average amount of short-acting
b-agonist use over a 1-year period, patients usingmultiple
inhalers simultaneously could appear to be high users if
they have received a high number of repeat prescriptions
during the study period, while, in reality, they may be
moderate or even low users.
One may question whether the low sensitivity and
PPV will also be found in other asthma populations. Of
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course, all validation scores are determined by the
underlying treatment pattern. Diﬀerences may be found,
for example, when b-agonist use is more indicative of
actual asthma severity than in the studied asthma pop-
ulation. However, this seems hardly likely, since treat-
ment patterns in this population are much in line with
that found in other countries in Europe [18].
This study emphasises the need for more information
regarding the validity of the indicators calculated from
computerised prescription data currently in use for
assessing treatment quality. Computerised data may be
easily available, however, in many instances, they may
not provide enough information to judge a doctors
performance. This is, in particular, the case in complex
diseases, such as asthma. Face and content validity, on
which validation has centred to date [33, 34, 35], are not
adequate substitutes for concurrent validity, checking if
an indicator adequately describes what can be observed
in actual clinical practice.
Prescribing indicators calculated from other data-
bases than a GP database will probably have lower
validity estimates than found in this study. If only
prescribing data and no indication is available (as in
sales data, claims data or pharmacist records),
misclassiﬁcation of patients occurs, undermining the
possibility of a valid assessment of prescribing quality
for a speciﬁc disease [29]. With the computerisation
in general practice, however, the availability of GP
databases and data on prescribing linked to indication
increases fast in Europe.
Before an indicator is used, information on its sen-
sitivity and PPV should be known. In the case of asthma
and other complex diseases, prescribing indicators can
only be used as a broad-brush approach to treatment
quality when additional information on asthma severity
class and actual use of asthma medications by the indi-
vidual patient is lacking. This is even more of the case
when no data are available that may link patients over
time to prescribing behaviour or in the absence of a
diagnosis. None of the commonly used asthma indica-
tors calculated from prescription databases that were
evaluated in this study can be considered a valid tool for
assessing the quality of doctors performance in the
management of asthma.
With the growing international interest in perfor-
mance indicators, this study emphasises the importance
of indicator validation and underlines that performance
indicators should only be used with caution.
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